10 July 2013Americas

Myriad sues Ambry over cancer gene screening tests

Biotech company Myriad Genetics has filed a patent infringement case against Ambry Genetic Corp for allegedly infringing 10 patents related to genetic diagnostic testing.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

US Supreme Court strikes Myriad blow

13 June 2013 The US Supreme Court has ruled that isolated human DNA is not patent eligible and has struck down patents owned by biotech company Myriad, ending a long-running and controversial case.

Americas

Myriad patent suit enters antitrust territory

8 August 2013 Ambry Genetics, the laboratory sued last month by biotech company Myriad over patents covering the BRCA1 and BRCA2 genes, has hit back with antitrust claims.

Americas

Myriad faces yet another patent battle

28 November 2013 Genetic diagnostics company Invitae Corporation has requested declaratory judgment at the US District Court for the Northern District of California that it does not infringe 11 patents owned or exclusively licensed to Myriad Genetics.

More on this story

Americas

US Supreme Court strikes Myriad blow

13 June 2013 The US Supreme Court has ruled that isolated human DNA is not patent eligible and has struck down patents owned by biotech company Myriad, ending a long-running and controversial case.

Americas

Myriad patent suit enters antitrust territory

8 August 2013 Ambry Genetics, the laboratory sued last month by biotech company Myriad over patents covering the BRCA1 and BRCA2 genes, has hit back with antitrust claims.

Americas

Myriad faces yet another patent battle

More on this story

Americas

US Supreme Court strikes Myriad blow

13 June 2013 The US Supreme Court has ruled that isolated human DNA is not patent eligible and has struck down patents owned by biotech company Myriad, ending a long-running and controversial case.

Americas

Myriad patent suit enters antitrust territory

8 August 2013 Ambry Genetics, the laboratory sued last month by biotech company Myriad over patents covering the BRCA1 and BRCA2 genes, has hit back with antitrust claims.

Americas

Myriad faces yet another patent battle